Abstract：
The present study aimed to determine whether current commercial immunoassays are adequate for detecting anti-Omicron antibodies. We analyzed the anti-SARS-CoV-2 antibody response of 23 unvaccinated individuals 1-2 months after an Omicron infection. All blood samples were tested with a live virus neutralization assay using a clinical Omicron BA.1 strain and four commercial SARS-CoV-2 immunoassays. We assessed three anti-Spike immunoassays (SARS-CoV-2 IgG II Quant [Abbott S], Wantaï anti-SARS-CoV-2 antibody ELISA [Wantaï], Elecsys Anti-SARS-CoV-2 S assay [Roche]) and one anti-Nucleocapsid immunoassay (Abbott SARS-CoV-2 IgG assay [Abbott N]). Omicron neutralizing antibodies were detected in all samples with the live virus neutralization assay. The detection rate of the Abbott S, Wantai, Roche, and Abbott N immunoassays were 65.2%, 69.6%, 86.9%, and 91.3%, respectively. The sensitivities of Abbott S and Wantai immunoassays were significantly lower than that of the live virus neutralization assay (p = 0.004, p = 0.009; Fisher\'s exact test). Antibody concentrations obtained with anti-S immunoassays were correlated with Omicron neutralizing antibody concentrations. These data provide clinical evidence of the loss of performance of some commercial immunoassays to detect antibodies elicited by Omicron infections. It highlights the need to optimize these assays by adapting antigens to the circulating SARS-CoV-2 strains.
摘要：
本研究旨在确定当前的商业免疫测定法是否足以检测抗Omicron抗体。我们分析了Omicron感染后1-2个月的23名未接种疫苗的个体的抗SARS-CoV-2抗体反应。使用临床OmicronBA.1菌株和四种商业SARS-CoV-2免疫测定用活病毒中和测定法测试所有血液样品。我们评估了三种抗刺性免疫测定法（SARS-CoV-2IgGIIQuant[AbbottS]，万泰抗SARS-CoV-2抗体ELISA[万泰]，Elecsys抗SARS-CoV-2S测定[Roche]）和一种抗核衣壳免疫测定（AbbottSARS-CoV-2IgG测定[AbbottN]）。用活病毒中和测定法在所有样品中检测Omicron中和抗体。雅培S的检出率，万泰,罗氏,雅培N免疫测定为65.2%，69.6%,86.9%,和91.3%，分别。雅培S和万泰免疫测定的灵敏度显着低于活病毒中和测定（p=0.004，p=0.009；Fisher精确检验）。用抗S免疫测定获得的抗体浓度与Omicron中和抗体浓度相关。这些数据提供了一些商业免疫测定法检测由Omicron感染引起的抗体的性能丧失的临床证据。它强调了通过使抗原适应循环的SARS-CoV-2菌株来优化这些测定的需要。
